Medtronic acquires Osteotech for $123m

- Last updated on GMT

Biologics company Medtronic has acquired Osteotech for $123m (€90.2m) in a step towards strengthening its business in regenerative biologics.

Osteotech specialises in biologic products for regenerative healing which will align with Medtronic’s current range of bone generating and biologic therapies used by surgeons.

“The acquisition complements our bone healing portfolio and will expand our current presence in spine, orthopedic trauma and dental into new treatment areas including joint reconstruction, foot and ankle, sports medicine and neurosurgery,”​ commented Tom McGuinness, general manager of Medtronic’s Biologics business.

“It will expand our reach into other musculoskeletal therapies and will accelerate our innovation and progress,”​ he added.

Related news

Show more

Related products

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more